Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | MCLA-158 |
Synonyms | |
Therapy Description |
MCLA-158 is a bispecific antibody that targets EGFR and LGR5, potentially resulting in decreased tumor growth (Cancer Res July 1 2017 (77) (13 Supplement) 32). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MCLA-158 | MCLA 158|MCLA158 | EGFR Antibody 43 | MCLA-158 is a bispecific antibody that targets EGFR and LGR5, potentially resulting in decreased tumor growth (Cancer Res July 1 2017 (77) (13 Supplement) 32). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03526835 | Phase I | MCLA-158 | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | Unknown status | USA | FRA | ESP | BEL | 0 |